MAAT INDEX

CLAIM #56322 · Thermo Fisher Scientific Inc (TMO) · 2023Q3 earnings call · Oct 25, 2023 · due Dec 31, 2023

And we now expect the free cash flow will be between $6.7 billion and $6.9 billion for the year.

Stephen Williamson · CFO

PENDING
graded after results covering Dec 31, 2023 are reported

How to check this claim

Look at: Full-year 2023 free cash flow

It came true if: Between $6.7 billion and $6.9 billion

Where: Company-reported free cash flow (Q4 2023 earnings release / 10-K cash flow statement)

In context

ss. Moving on to FX. Given recent rate changes, we're now assuming that FX will be a year-over-year headwind to revenue of approximately $100 million. And in terms of adjusted EPS, we now expect FX to be a year-over-year headwind of $0.28 which is $0.17 more of a headwind than our previous guidance. The Binding Site and CorEvitas acquisitions are performing well, and we now assume that they'll contribute approximately $300 million to our reported revenue growth for the year. Below the line, we now expect just under $500 million of net interest expense in 2023, a slight increase reflecting the acquisition of CorEvitas. We continue to assume that the adjusted tax rate for the -- 2023 will be 10%, and we're now expecting net capital expenditures will be between $1.3 billion and $1.5 billion. And we now expect the free cash flow will be between $6.7 billion and $6.9 billion for the year. In terms of capital deployment, our guidance includes $3 billion of share buybacks, which were already completed in January, $3.7 billion in acquisitions completed this year, and $3.1 billion committed to the acquisition of Olink, which we expect to close in 2024. We continue to assume that full-year average diluted share count will be approximately 388 million shares, and then we'll return approximately $540 million of capital to shareholders this year through dividends, a 17% increase over 2022. So before I conclude my prepared remarks, I thought it'd be helpful to share some more detailed thoughts around how to frame 2024. At this point in time, a good starting assumption is that our core organic revenue growth in 2024 is similar to 2023, approximately 1% growth. With our proven growth

Verify independently

SEC filings for TMO · Claim quote is verbatim from the 2023Q3 earnings call.